Cargando…

Health state utilities associated with attributes of weekly injection devices for treatment of type 2 diabetes

BACKGROUND: Glucagon-like peptide-1 (GLP-1) receptor agonists are often recommended as part of combination therapy for type 2 diabetes when oral medication does not result in sufficient glycemic control. Several GLP-1 receptor agonists are available as weekly injections. These medications vary in th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Matza, Louis S., Boye, Kristina S., Stewart, Katie D., Davies, Evan W., Paczkowski, Rosirene
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5702146/ https://www.ncbi.nlm.nih.gov/pubmed/29178918 http://dx.doi.org/10.1186/s12913-017-2648-7

Ejemplares similares

Development of the Diabetes Injection Device Experience Questionnaire (DID-EQ) and Diabetes Injection Device Preference Questionnaire (DID-PQ)
por: Matza, Louis S., et al.
Publicado: (2018)

Psychometric evaluation of the Diabetes Injection Device Experience Questionnaire (DID-EQ) and Diabetes Injection Device Preference Questionnaire (DID-PQ)
por: Matza, Louis S., et al.
Publicado: (2018)

Patient preferences in Italy: health state utilities associated with attributes of weekly injection devices for treatment of type 2 diabetes
por: Matza, Louis S, et al.
Publicado: (2018)

Evaluating preferences for profiles of GLP-1 receptor agonists among injection-naïve type 2 diabetes patients in the UK
por: Gelhorn, Heather L, et al.
Publicado: (2015)

Health state utilities associated with treatment process for oral and injectable GLP-1 receptor agonists for type 2 diabetes
por: Matza, Louis S., et al.
Publicado: (2021)

Validity and analysis of the Diabetes Injection Device Preference Questionnaire (DID-PQ)
por: Boye, Kristina S., et al.
Publicado: (2020)

Development of a Patient-Reported Outcome (PRO) Measure to Assess Emotional Impact of Treatment for Type 2 Diabetes
por: Boye, Kristina S., et al.
Publicado: (2023)

The Association Between Sustained HbA1c Control and Long-Term Complications Among Individuals with Type 2 Diabetes: A Retrospective Study
por: Boye, Kristina S., et al.
Publicado: (2022)

Development of a patient-reported outcome (PRO) measure to assess patient perceptions of simplicity and complexity of treatment for type 2 diabetes
por: Stewart, Katie D., et al.
Publicado: (2023)

Health state utilities associated with attributes of treatments for hepatitis C
por: Matza, Louis S., et al.
Publicado: (2014)

Exit Interviews Examining the Patient Experience in Clinical Trials of Tirzepatide for Treatment of Type 2 Diabetes
por: Matza, Louis S., et al.
Publicado: (2022)

A qualitative examination of the content validity of the EQ-5D-5L in patients with type 2 diabetes
por: Matza, Louis S., et al.
Publicado: (2015)

Patient Perceptions of and Preferences Between Characteristics of Injectable Diabetes Treatments
por: Boye, Kristina S., et al.
Publicado: (2021)

Validation of two generic patient-reported outcome measures in patients with type 2 diabetes
por: Matza, Louis S, et al.
Publicado: (2007)

Patient Preferences and Health State Utilities Associated with Mealtime Insulin Concentrations Among Patients with Diabetes in Italy
por: Matza, Louis S., et al.
Publicado: (2019)

Acute and chronic impact of cardiovascular events on health state utilities
por: Matza, Louis S, et al.
Publicado: (2015)

Health state utilities associated with attributes of migraine preventive treatments based on patient and general population preferences
por: Matza, Louis S., et al.
Publicado: (2019)

Impact of caregiver and parenting status on time trade-off and standard gamble utility scores for health state descriptions
por: Matza, Louis S, et al.
Publicado: (2014)

The time horizon matters: results of an exploratory study varying the timeframe in time trade-off and standard gamble utility elicitation
por: Matza, Louis S., et al.
Publicado: (2015)

Health state utilities associated with treatment for transfusion-dependent β-thalassemia
por: Matza, Louis S., et al.
Publicado: (2019)

Risks associated with antiretroviral treatment for human immunodeficiency virus (HIV): qualitative analysis of social media data and health state utility valuation
por: Matza, Louis S., et al.
Publicado: (2017)

Glycemic and Economic Outcomes in Elderly Patients with Type 2 Diabetes Initiating Dulaglutide Versus Basal Insulin in a Real-World Setting in the United States: The DISPEL-Advance Study
por: Hoog, Meredith, et al.
Publicado: (2023)

Preference for pharmaceutical formulation and treatment process attributes
por: Stewart, Katie D, et al.
Publicado: (2016)

Evaluating the Impact of Therapy on Quality of Life in Type 2 Diabetes: A Literature Review of Utilities Associated with Treatment-Related Attributes
por: Valentine, William, et al.
Publicado: (2022)

Health state utilities associated with adult attention-deficit/hyperactivity disorder
por: Matza, Louis S, et al.
Publicado: (2014)

The longitudinal link between visual acuity and health-related quality of life in patients with diabetic retinopathy
por: Matza, Louis S, et al.
Publicado: (2008)

Health state utilities for skeletal-related events secondary to bone metastases
por: Matza, Louis S., et al.
Publicado: (2013)

Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes
por: Secnik Boye, Kristina, et al.
Publicado: (2006)

Patients' preferences for once‐daily oral versus once‐weekly injectable diabetes medications: The REVISE study
por: Boye, Kristina, et al.
Publicado: (2020)

Health-related quality of life burden of nonalcoholic steatohepatitis: a robust pragmatic literature review
por: Kennedy-Martin, Tessa, et al.
Publicado: (2018)

Health state utilities associated with major clinical events in the context of secondary hyperparathyroidism and chronic kidney disease requiring dialysis
por: Davies, Evan W., et al.
Publicado: (2015)

Timing of GLP-1 Receptor Agonist Initiation for Treatment of Type 2 Diabetes in the UK
por: Boye, Kristina S., et al.
Publicado: (2019)

Health state utilities associated with hyperphagia: Data for use in cost‐utility models
por: Howell, Timothy A., et al.
Publicado: (2023)

Treatment-Related Attributes of Diabetes Therapies and How People with Type 2 Diabetes Report Their Impact on Indicators of Medication-Taking Behaviors
por: Sims, Tracy J, et al.
Publicado: (2022)

Utilities associated with subcutaneous injections and intravenous infusions for treatment of patients with bone metastases
por: Matza, Louis S, et al.
Publicado: (2013)

Patient-Reported Outcomes and Impact of Type 2 Diabetes: A Cross-Sectional Study in the Kingdom of Saudi Arabia
por: Gelhorn, Heather L, et al.
Publicado: (2020)

Patient preferences and health state utilities associated with the treatment process of antiretroviral therapy for people living with HIV
por: Matza, Louis S., et al.
Publicado: (2022)

Which multi-attribute utility instruments are recommended for use in cost-utility analysis? A review of national health technology assessment (HTA) guidelines
por: Kennedy-Martin, Matthew, et al.
Publicado: (2020)

Health state utilities associated with post-surgical Staphylococcus aureus infections
por: Matza, Louis S., et al.
Publicado: (2019)

Understanding the impact of five major determinants of health (genetics, biology, behavior, psychology, society/environment) on type 2 diabetes in U.S. Hispanic/Latino families: Mil Familias - a cohort study
por: Morales, Jessikah, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_pt7d8t8nm9vtcaa6lfqjj164ig